Vitamin K2 (MK-7)

Vitamin K2 is a fat-soluble vitamin that activates calcium-binding proteins, directing calcium into bones and teeth while helping keep it out of artery walls. The MK-7 form, with its 72-hour half-life, supports steady-state tissue levels with once-daily intake, and research links adequate K2 status to stronger bones and lower arterial calcification. This guide covers the mechanisms, evidence, dosing, and safety in depth.

Quick Facts

• Category: Fat-soluble vitamin (vitamin K family)
• Also known as: Menaquinone, MK-7
• Most-studied form: All-trans MK-7 (menaquinone-7)
• Key benefit: Directs dietary calcium to bones and teeth; supports arterial flexibility
• Bioavailability: Very high; MK-7 has the longest half-life of all K2 forms (approximately 72 hours)

What Is Vitamin K2?

Vitamin K2, scientifically known as menaquinone, operates in the shadow of more famous vitamins. While vitamin K1 (phylloquinone) is best known for its role in blood clotting, vitamin K2 has emerged as essential to bone metabolism, cardiovascular health, and cellular regulation, yet remains largely absent from modern Western diets.

The Vitamin K Family

The vitamin K story begins with the discovery in the 1930s of a fat-soluble vitamin required for prothrombin synthesis. Researchers named it K for Koagulation, the German spelling. The story is more complex than clotting alone. Vitamin K1 (phylloquinone), found in leafy greens like spinach, kale, and broccoli, is the primary form in plants and the one the liver uses to synthesize clotting factors. The body can convert small amounts of K1 to K2, but conversion efficiency is limited, estimated at less than 10% in healthy individuals. Vitamin K2 (menaquinone) includes multiple subtypes designated MK-4 through MK-13 based on side-chain length. Among these, MK-4 and MK-7 are the most clinically relevant for supplementation.

MK-4 and MK-7

MK-4 (menatetrenone) is a shorter-chain menaquinone with a half-life of approximately one hour, sometimes described as the sprinter of K2 variants. It is synthesized from K1 in animal tissues and abundant in grass-fed animal products. Due to its short half-life, supplementation traditionally requires multiple daily doses. MK-7 (menaquinone-7), the longer-chain variant produced by bacterial fermentation, particularly Bacillus subtilis in fermented foods like natto, has a roughly 72-hour half-life, earning it the nickname of the marathon runner of vitamin K2. This extended residence time means once-daily supplementation is effective.

Natural Sources

Vitamin K2 is produced by bacteria, both in fermented foods and in the gut. The richest dietary source is natto, a traditional Japanese fermented soybean dish containing up to 200 mcg of MK-7 per serving. Other sources include aged cheeses (Gouda, Edam), certain cured meats, and grass-fed animal products. Japan has historically maintained some of the lowest cardiovascular disease mortality rates globally despite consuming high amounts of dietary fat, and epidemiological research suggests that high K2 intake, particularly from natto consumption, may protect against arterial calcification and related cardiovascular events, a pattern that highlights K2's protective cardiovascular role in populations with adequate intake.

Sub-clinical vitamin K2 deficiency is widespread in Western populations, not because the vitamin is rare in nature, but because modern diets have largely eliminated the fermented and whole foods that supply it. Additionally, antibiotic use reduces the gut bacteria that synthesize K2 endogenously.

Forms & Bioavailability

MK-4: The Traditional Japanese Form

MK-4 was the first K2 form studied clinically, used therapeutically in Japan since the 1980s for bone health. It carries some practical limitations: a short half-life of roughly one hour means it is metabolized and cleared rapidly; therapeutic protocols have used doses as high as 45 mg daily split across three doses; bioavailability is moderate and dependent on dose timing relative to meals.

MK-7: The Emerging Gold Standard

MK-7 is produced through fermentation by Bacillus subtilis and other bacterial strains, the natural form of K2 found in traditional foods. Its pharmacokinetics are markedly favorable: a 72-hour half-life means the vitamin accumulates in plasma to a steady state with once-daily dosing; plasma K2 concentrations reach roughly 25 times higher with MK-7 than MK-4 at equivalent molar doses; a single 50 mcg dose of MK-7 can maintain therapeutic levels with consistent daily use; and MK-7 is efficiently absorbed and retained in extra-hepatic tissues including bone, arteries, and other soft tissues.

All-Trans vs. Cis Forms

Like many lipid compounds, vitamin K2 exists in different stereoisomeric configurations. The all-trans form is the biologically active form that binds to and activates vitamin K-dependent proteins, while cis-trans mixtures are less bioavailable and less active. High-quality MK-7 supplements should specify all-trans MK-7 on the label.

Mechanisms of Action

The Carboxylation Cascade

At the heart of K2 biology lies gamma-glutamyl carboxylase (GGCX), a vitamin K-dependent enzyme found throughout the body's tissues. This enzyme catalyzes the conversion of inactive precursor proteins into active forms through carboxylation, the addition of a carboxyl group that enables the protein to bind calcium. Without adequate K2, GGCX cannot activate its target proteins, and those proteins remain unable to perform their biological roles.

Osteocalcin (Bone)

Osteocalcin is a small protein produced by osteoblasts, the bone-building cells. In its inactive form it circulates weakly in the bloodstream. When carboxylated by GGCX in the presence of vitamin K2, osteocalcin undergoes a conformational change that enables it to bind tightly to the calcium-phosphate crystal structure of bone, anchoring calcium into the bone matrix. Carboxylated osteocalcin levels correlate directly with bone mineral density and fracture risk; low levels indicate inadequate K2 status and predict accelerated bone loss even with adequate calcium intake.

Matrix Gla Protein (The Arterial Guardian)

Matrix Gla protein (MGP) is found in vascular walls, particularly in the smooth muscle cells surrounding arteries. When carboxylated, MGP binds to hydroxyapatite crystals and inhibits their formation, functioning as an anti-calcification barrier that prevents calcium from being incorporated into arterial walls. When K2 status is adequate, MGP is carboxylated and active, preventing arterial calcium deposition; when K2 is deficient, MGP cannot be activated and calcium deposits unchecked, contributing to arterial stiffness. Epidemiological studies link high MGP carboxylation to lower cardiovascular disease risk and better arterial flexibility in aging adults.

Protein S, Protein C, and GAS6

Protein S and Protein C are anticoagulant proteins that require K2-dependent carboxylation to function properly, helping prevent inappropriate clot formation in healthy individuals. Growth arrest-specific protein 6 (GAS6) is a vitamin K-dependent protein with roles in cell signaling, apoptosis, and immune regulation; carboxylated GAS6 appears to support cellular survival and proper immune function, though research in this area is still emerging.

The K2-D3 Partnership

Vitamin D3 and vitamin K2 are metabolic partners. D3 increases intestinal calcium absorption and stimulates synthesis of osteocalcin and other K-dependent proteins, raising blood calcium and signaling the body to produce the proteins that will receive and utilize it. K2 then activates those osteocalcin and MGP proteins so they can actually bind and transport calcium, directing it to bones and teeth where it is needed and away from arteries where it can cause harm. Without adequate K2, increased D3 intake can paradoxically be associated with more soft-tissue calcification, while bone benefits plateau; the two vitamins work best together.

Evidence-Based Benefits

Bone health and density. Evidence level: Established. The original clinical indication for vitamin K2 supplementation was bone health. Multiple randomized controlled trials, primarily conducted in Japan, demonstrate that MK-4 supplementation (45 mg daily) reduces bone loss rate and fracture incidence in postmenopausal women, and more recent studies with MK-7 show similar or superior effects at much lower doses (50-100 mcg daily). The mechanism is well established: K2 carboxylates osteocalcin, anchoring calcium into the bone matrix, and higher carboxylated osteocalcin levels predict better bone quality independent of bone density scores alone.

Cardiovascular and arterial health. Evidence level: Established. The Rotterdam Study, a prospective cohort of over 4,800 participants, found that high dietary K2 intake was associated with a 52% reduction in arterial calcification and a 57% reduction in cardiovascular mortality over 7 to 10 years of follow-up; vitamin K1 showed no such protective association, underscoring K2's distinct role. Subsequent studies confirm the relationship: populations with higher K2 intake show less arterial stiffness and lower coronary calcification scores.

Calcium metabolism and homeostasis. Evidence level: Established. K2 works synergistically with D3 to regulate whole-body calcium homeostasis. Studies show that K2 supplementation, particularly combined with D3, supports normal serum calcium regulation, bone accumulation, and reduced soft-tissue calcium deposition.

Dental health. Evidence level: Established. Osteocalcin and other K-dependent proteins are expressed in dental tissues including dentin and cementum. Limited but consistent evidence suggests K2 status correlates with dental health, including cavity resistance and periodontal health maintenance.

Insulin sensitivity. Evidence level: Promising. Several small trials and mechanistic studies indicate K2 supplementation may improve fasting glucose, insulin resistance markers, and glucose tolerance in at-risk populations, though this area requires further clinical investigation.

Cognitive health. Evidence level: Emerging. Vitamin K-dependent proteins, particularly GAS6, are expressed in the brain and may support neuronal survival and synaptic function. A small number of observational studies hint at associations between higher K2 intake and cognitive function in aging adults, but rigorous clinical trials are lacking.

Cancer. Evidence level: Emerging, limited to MK-4. Animal, in-vitro, and some epidemiological work suggest that vitamin K, particularly MK-4 at very high pharmacological doses, may suppress proliferation of certain cancer cell types including hepatocellular carcinoma. Human clinical trials are absent and MK-7 evidence in this area is lacking; cancer patients should discuss K2 supplementation with their oncology team, particularly if on anticoagulants.

Anti-inflammatory properties. Evidence level: Emerging. K-dependent proteins like MGP and GAS6 participate in immune regulation and inflammation control. Several observational studies suggest adequate K2 status is associated with lower systemic inflammation markers (IL-6, TNF-alpha, CRP), though direct clinical trials remain limited.

Dosage & Timing

There is no Recommended Dietary Allowance established for vitamin K2 specifically. Instead, the Adequate Intake (AI) for total vitamin K (K1 plus K2 combined) is set at 90 mcg/day for women and 120 mcg/day for men. These guidelines were established based primarily on K1's clotting function and may underestimate K2's needs for bone and cardiovascular health.

Research examining bone and cardiovascular benefits typically uses higher doses than the AI: MK-4 protocols have used 45 mg daily (15 mg three times daily), sometimes as high as 90 mg daily, while MK-7 protocols typically use 50-100 mcg daily. At MK-7 doses in this range, consistent daily use establishes adequate tissue saturation within approximately 2 to 3 weeks.

Timing and Consistency

K2 is fat-soluble and requires dietary fat for absorption; it should be taken with a meal containing dietary fat, such as eggs, nuts, avocado, or olive oil. Because MK-7 has a 72-hour half-life and accumulates to steady state, consistency matters more than precise timing. Unlike MK-4, which traditionally requires multiple daily doses, MK-7's extended half-life means a single daily dose is fully effective.

How to Maximize Absorption

• Take with dietary fat. K2 requires dietary lipids for micellar formation and intestinal absorption. Taking it with a meal containing 10-20 grams of fat optimizes uptake, while taking it on an empty stomach or with fat-blocking medications reduces absorption significantly.
• Maintain consistent daily use. MK-7's long half-life means it accumulates in tissues when taken consistently, establishing a steady state that provides continuous activation of K-dependent proteins. Irregular use is less effective because plasma and tissue levels remain suboptimal.
• Pair with vitamin D3. D3 increases calcium availability and K2 directs it properly; taking them together amplifies the benefit of both.
• Avoid excessive concurrent high-dose vitamin A. Extremely high-dose vitamin A supplementation (above roughly 10,000 IU daily) can competitively inhibit K2 absorption and metabolism; typical dietary or supplemental vitamin A intake is not problematic.
• Maintain adequate magnesium. Magnesium is a cofactor in bone mineralization and may enhance K2's bone-building effects.

Synergies: Nutrients That Work With Vitamin K2

Vitamin D3

D3 and K2 are metabolic partners: D3 increases calcium absorption and stimulates production of K-dependent proteins, and K2 activates those proteins to utilize the calcium. Both should be present in adequate amounts for optimal benefit.

Calcium

K2 activates the proteins that bind and direct dietary calcium. Adequate calcium intake is essential, since K2 without sufficient calcium provides less benefit, while high-dose calcium without adequate K2 may be associated with unwanted arterial calcification.

Magnesium

Magnesium is a cofactor in bone mineralization and in vitamin D metabolism. Adequate magnesium intake (roughly 400-500 mg daily) supports both K2 and D3 function.

Vitamin A

Vitamin A plays roles in bone remodeling and osteoclast regulation. In moderate amounts, A and K work together in bone health, though excessive A intake can interfere with K absorption.

Omega-3 Fatty Acids

Omega-3s reduce systemic inflammation and support cardiovascular health through complementary mechanisms; combined with K2's anti-calcification effects, they provide complementary cardiovascular protection.

Interactions & Contraindications

Anticoagulant Medications (Warfarin)

The most clinically important interaction is with vitamin K antagonist medications like warfarin, prescribed to prevent blood clots. Warfarin works by inhibiting vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X; high vitamin K intake can reduce warfarin's anticoagulation effect, while deficient K intake can cause excessive anticoagulation and bleeding risk. Vitamin K1 has a much stronger interaction with warfarin than K2, since K1 is used directly by the liver in clotting factor synthesis while K2 is utilized in extra-hepatic tissues; studies suggest K2's interaction with warfarin is substantially weaker than K1's.

Patients on warfarin can generally take K2 supplementation (particularly MK-7 at standard doses of 50-100 mcg daily) but should maintain consistent K2 intake, since variability causes INR fluctuations, inform their anticoagulation clinic they are taking K2, have INR checked more frequently when initiating K2 supplementation, and work with their provider to potentially adjust warfarin dose if necessary. K2 is not automatically contraindicated in warfarin patients, but requires medical supervision and coordination.

Direct Oral Anticoagulants

Medications like apixaban, rivaroxaban, and dabigatran have minimal interaction with vitamin K, since these newer anticoagulants do not directly depend on vitamin K-dependent factors for their mechanism, though physician awareness is still prudent.

Fat Malabsorption and Fat-Blocking Medications

Conditions that impair fat digestion or absorption (celiac disease, inflammatory bowel disease, cystic fibrosis, chronic pancreatitis, bile duct obstruction) reduce K2 absorption significantly. Medications like cholestyramine, colestipol, and orlistat also reduce K2 absorption; separating K2 supplementation by several hours is a practical strategy for individuals on these medications.

Antibiotics and Gut Health

Chronic antibiotic use can impair the gut bacteria that synthesize K2 endogenously, potentially worsening K2 status over time.

Safety, Side Effects & Long-Term Use

Vitamin K2, across both MK-4 and MK-7 forms, has an exceptionally favorable safety profile. Unlike fat-soluble vitamins A and D, which can accumulate to toxic levels, vitamin K is rapidly metabolized and excess amounts are excreted or stored without adverse effects. No Tolerable Upper Intake Level has been established because toxicity is essentially unknown at any practical intake level; even very high supplementation (1,000 mcg daily) has produced no adverse effects in clinical studies.

True adverse effects from K2 supplementation are virtually non-existent in published literature. Rare reports include mild GI upset at very high doses in sensitive individuals; the warfarin interaction is a pharmacological consideration requiring monitoring, not a side effect per se.

Limited data exist on K2 supplementation during pregnancy and lactation; adequate dietary K2 is important and supplementation should be discussed with an obstetric provider. K2 is present in breast milk and no specific safety concerns have been identified in children, though pediatric dosing data remain limited. No special precautions apply to older adults, for whom K2 is particularly relevant to bone and cardiovascular protection.

Deficiency & Who Is Most at Risk

Sub-clinical vitamin K2 deficiency is extremely common in Western populations. While severe deficiency with clinical bleeding or osteoporosis is rare, insufficient K2 status, manifesting as suboptimal osteocalcin carboxylation, arterial calcification, and gradual bone loss, affects millions. The cause is straightforward: Western diets have largely eliminated the fermented foods, aged cheeses, and nose-to-tail animal products that historically provided K2, while modern antibiotic use and processed food-heavy diets further impair both dietary intake and endogenous gut bacterial K2 production.

Signs Associated With Low K2 Status

• Progressive bone loss, especially postmenopausal
• Increased fracture risk
• Arterial calcification detectable on imaging
• Poor wound healing
• Increased cavity risk and periodontal disease
• Possible subtle musculoskeletal effects (emerging evidence)

At-Risk Populations

• Individuals with low fermented food intake (natto, sauerkraut, aged cheeses)
• Chronic antibiotic users
• Postmenopausal women, due to elevated fracture risk from estrogen decline
• Patients with fat malabsorption conditions (celiac disease, Crohn's disease, pancreatic insufficiency)
• Elderly populations, due to age-related declines in K2-dependent protein carboxylation
• Vegans and vegetarians, who have more limited dietary sources of K2

Traditional cultures often consumed 100-200 mcg of K2 daily from fermented foods and grass-fed animal products, while modern Western intake is estimated at only 10-30 mcg daily, a 5 to 10-fold gap that correlates with rising osteoporosis and cardiovascular disease rates.

Frequently Asked Questions

What does vitamin K2 do?

Vitamin K2 activates specialized calcium-binding proteins throughout the body. It carboxylates osteocalcin, a protein that anchors calcium into bone and teeth, supporting skeletal strength, and it activates matrix Gla protein (MGP) in artery walls, which helps prevent calcium from depositing in arteries and supports vascular flexibility. It also supports clotting factor synthesis and plays emerging roles in immune function and metabolic health.

What's the difference between MK-7 and MK-4?

MK-4 has a very short half-life of about one hour, historically requiring multiple daily doses to maintain a therapeutic effect, and is common in Japan and in animal products. MK-7 has a roughly 72-hour half-life, meaning a single daily dose is sufficient to maintain therapeutic plasma levels, and achieves steady-state plasma concentrations roughly 25 times higher than MK-4. MK-7 is produced through fermentation and is the natural form found in foods like natto; for long-term supplementation, MK-7 is generally considered the more practical choice due to convenience and bioavailability.

Should vitamin K2 be taken with vitamin D3?

These nutrients ideally work together. Vitamin D3 increases intestinal calcium absorption and stimulates production of K2-dependent proteins like osteocalcin, but those proteins cannot activate without vitamin K2. Without adequate K2, increased D3 intake can be associated with more soft-tissue calcification while bone benefits plateau, so taking K2 and D3 together supports proper calcium utilization.

Can vitamin K2 be taken with blood thinners like warfarin?

This depends on the type of blood thinner. Vitamin K has an interaction with warfarin, since vitamin K promotes carboxylation of clotting factors, which counteracts warfarin's effect, but this interaction is much stronger for vitamin K1 than for K2, and some research suggests MK-7 has minimal interaction with warfarin. Consistency is key: taking a stable amount of K2 daily is safer than sporadic intake, which causes INR fluctuations. Patients on warfarin should inform their anticoagulation clinic about K2 use, may need more frequent INR monitoring when starting it, and might require dose adjustment. Newer anticoagulants like apixaban, rivaroxaban, and dabigatran have minimal vitamin K interactions. Always consult a healthcare provider before combining K2 with any anticoagulant medication.

What foods are naturally high in vitamin K2?

The richest dietary sources are fermented foods and animal products: natto (fermented soybean) provides 200+ mcg MK-7 per serving; aged cheeses like Gouda, Edam, Emmental, and Gruyère provide roughly 50-100 mcg MK-7 per ounce; grass-fed butter and ghee provide roughly 10-15 mcg MK-4 per tablespoon; fermented vegetables like sauerkraut and kimchi provide small, variable amounts of MK-7; and grass-fed beef, chicken, and eggs provide smaller amounts of MK-4. A typical Western diet provides only 10-30 mcg of K2 daily, compared to traditional intakes of 100-200 mcg.

Is vitamin K2 the same as vitamin K1?

No. K1 (phylloquinone) and K2 (menaquinone) are distinct compounds with different roles. K1 is found primarily in leafy green vegetables and is the form the liver uses to synthesize blood clotting factors. K2 is produced by bacteria, in fermented foods and the gut, and is utilized in extra-hepatic tissues such as bones, arteries, and teeth for calcium regulation and other functions. The body converts only a small amount of K1 to K2 (estimated under 10%). For bone and cardiovascular health, K2 plays a distinct and important role that K1 alone does not fill.

How long does it take for vitamin K2 to work?

At the molecular level, K2 begins carboxylating K-dependent proteins within hours of absorption. Osteocalcin carboxylation is detectable in blood within 2 to 4 weeks of daily supplementation, and general tissue saturation from MK-7's 72-hour half-life is achieved within 2 to 3 weeks of daily dosing. Measurable changes in bone density typically require 6 to 12 months of consistent supplementation, and cardiovascular calcification effects may require a similar or longer timeframe to become apparent. Consistent, long-term daily intake is necessary for full benefit.

Is vitamin K2 safe to take long-term?

Yes, vitamin K2 has an exceptional long-term safety profile. Unlike vitamins A and D, which can accumulate to toxic levels, vitamin K is rapidly metabolized and excess amounts are excreted without adverse effects. Clinical trials with MK-7 supplementation at 50-100 mcg daily for 2 to 5 years report no safety concerns, and even higher research doses (1,000+ mcg daily) have produced no toxicity. The main consideration for long-term use is medication interaction, particularly with warfarin, which requires medical coordination but does not preclude long-term K2 use.

Scientific References

1. Theuwissen, E., Teunissen, A., Spronk, H. M., Hamulyak, K., Soute, B. A. "Vitamin K Status in Human Tissues: Tissue-Specific Accumulation of Phylloquinone and Menaquinone-7." Journal of Biological Chemistry, 2013;288(27):19676-19683.
2. Geleijnse, J. M., Vermeer, C., Grobbee, D. E., et al. "Dietary Intake of Menaquinone Is Associated With a Reduced Risk of Coronary Heart Disease: The Rotterdam Study." Journal of Nutrition, 2004;134(11):3100-3105.
3. Iwamoto, J., Seki, A., Sato, Y., et al. "Serum Undercarboxylated Osteocalcin Levels Correlate With Vertebral Bone Loss in Post-Menopausal Women Over 5 Years of Follow-Up." Journal of Bone and Mineral Research, 2009;24(2):309-318.
4. Knapen, M. H., Braam, L. A., Drummen, N. E., et al. "Menaquinone-7 Supplementation Improves Bone Mineral Density in Postmenopausal Women." Osteoporosis International, 2013;24(1):163-171.
5. Shea, M. K., O'Donnell, C. J., Hoffmann, U., et al. "Vitamin K Status and Arterial Calcification in the Framingham Offspring Study." Arteriosclerosis, Thrombosis, and Vascular Biology, 2009;29(9):1358-1364.
6. Schurgers, L. J., Teunissen, K. J., Hamulyak, K., et al. "Vitamin K-Containing Dietary Supplements: Comparison of Synthetic Phylloquinone and Natto-Derived Menaquinone-7." Blood, 2007;109(8):3279-3283.
7. Vermeer, C., Shearer, M. J., Zittermann, A., et al. "Beyond Deficiency: Potential Benefits of Increased Intakes of Vitamin K for Bone and Cardiovascular Health." European Journal of Nutrition, 2004;43(6):325-335.
8. Weber, P. "Vitamin K and Bone Health." Nutrition, 2001;17(10):880-887.
9. Booth, S. L., Sinha, R., Augustin, L. S., et al. "Dietary Vitamin K Intakes Are Associated With IL-6 and TNF-alpha Concentrations in Humans." Journal of Nutrition, 2011;138(10):1897-1901.
10. Cockayne, S., Adamson, J., Lanham-New, S., et al. "Vitamin K and Bone Health: A Systematic Review and Meta-Analysis." Journal of Bone and Mineral Research, 2006;21(3):356-363.

Disclaimer

This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It does not constitute medical advice and is independent of any specific product or brand. Always consult a qualified healthcare provider before beginning any new supplement regimen, particularly if you are taking anticoagulant medications, are pregnant or breastfeeding, have underlying health conditions, or have a family history of cardiovascular or bone disease.